Significantly more psoriasis patients randomized to a 0.25% desoximetasone spray showed clinical success and treatment success, compared with those who used a placebo vehicle, based on data from a pair of phase III studies. The findings were published in the December issue of Journal of Drugs in Dermatology by Dr. Leon Kircik of Indiana University School of Medicine, Indianapolis, and his colleagues.
The study population included adults with moderate to severe plaque psoriasis. The patients used the spray twice daily for 28 days, and they were assessed at baseline and during the study using the Physician Global Assessment score and the Total Lesion Severity Score. No significant differences in adverse events were reported between the treatment and placebo groups, and no patients reported stinging or burning from the spray formulation (J. Drugs Dermatol. 2013;12:1404-10).